Rick Doblin at the 2023 Psychedelic Science conference in Denver (Courtesy of Psychedelic Science and MAPS)
September 17, 2024 10:00 AM EDT
People
In Focus

Bad trip: How cul­ture con­flict and a need for cash near­ly broke Lykos

Max Bayer

Pharma Reporter

In ear­ly 2023, the founder of the psy­che­del­ic med­i­cine com­pa­ny Lykos Ther­a­peu­tics met with a po­ten­tial in­vestor for din­ner, feel­ing out the chem­istry for a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times